am 580 has been researched along with Disease Exacerbation in 1 studies
Am 580: a selctive retinoic acid receptor (alpha) agonist; structure given in first source
4-{[(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)carbonyl]amino}benzoic acid : An amidobenzoic acid obtained by formal condensation of the carboxy group of (5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)benzoic acid with the anilino group of 4-aminobenzoic acid. A selective RARalpha agonist.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhong, Y | 1 |
| Wu, Y | 1 |
| Liu, R | 1 |
| Deng, Y | 1 |
| Mallipattu, SK | 1 |
| Klotman, PE | 1 |
| Chuang, PY | 1 |
| He, JC | 1 |
1 other study available for am 580 and Disease Exacerbation
| Article | Year |
|---|---|
Roflumilast enhances the renal protective effects of retinoids in an HIV-1 transgenic mouse model of rapidly progressive renal failure.
Topics: AIDS-Associated Nephropathy; Aminopyridines; Animals; Benzamides; Benzoates; Cell Differentiation; C | 2012 |